Salvage Therapies After Anti‐BCMA CAR‐T Failure in Patients With Multiple Myeloma: A Meta‐Analysis of Response Rates
European Journal of Haematology · 2026-05 · 116 (5) · 663-673
DOI: 10.1111/ejh.70123 ↗Kurz gefasst
Metaanalyse in der Zeitschrift European Journal of Haematology, online erschienen am 27.01.2026. Verfasst von Jaromir Tomasik und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, Warsaw, Poland. Hauptthemen laut MEDLINE: Multiple Myeloma, Salvage Therapy, Immunotherapy, Adoptive, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben.
Abstract (Originalsprache)
Although chimeric antigen receptor (CAR)‐T cells targeting B‐cell maturation antigen (BCMA) have significantly advanced multiple myeloma (MM) therapy, many patients eventually progress, prompting the search for the most effective salvage regimens. To address this demand, we performed a random‐effects meta‐analysis evaluating response rates to salvage treatments after anti‐BCMA CAR‐T failure. We identified 36 eligible studies comprising 476 patients and seven distinct interventions through systematic database screening. Among them, bispecific antibodies (bsAbs) were the most common choice, followed by anti‐BCMA CAR‐T cells. We separately assessed response rates to both first‐ and any subsequent (combined)‐line salvage interventions. In the first‐line setting, selinexor‐based regimens yielded the highest overall response rates (ORR) of 67% (95% CI: 38%–91%), followed by bsAbs (60%; 95% CI: 43%–76%). In the combined setting, anti‐GPRC5D CAR‐T cells achieved the highest ORR (88%; 95% CI: 65%–100%), followed by anti‐BCMA CAR‐T cells (75%; 95% CI: 42%–98%). Belantamab mafodotin demonstrated the lowest efficacy (0%; 95% CI: 0%–17%). Complete response rates remained low across all interventions (range: 0%–40%). Heterogeneity investigations revealed superior responses with human/humanized anti‐BCMA CAR‐T constructs compared with the animal‐based receptors. In summary, our meta‐analysis suggested that CAR‐T cells and bsAbs are suitable for salvage use after anti‐BCMA CAR‐T failure in MM. Trial Registration: PROSPERO number: CRD42024621077
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, Warsaw, Poland.
- Doctoral School, Medical University of Warsaw, Warsaw, Poland.
- Department of Medicine, Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Department of Medicine, Weill Cornell Medical College, New York, New York, USA.
- Department of Medicine A and Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, Petah-Tikva, Israel.
- Faculty of Medical and Health Sciences, Tel Aviv University, Tel-Aviv, Israel.
ORCID-Profile: Jaromir Tomasik
Zitieren
APA
Tomasik, J., Shouval, R., Gafter-Gvili, A., Topiłko, J., Bilicki, D., & Basak, G. W. (2026). Salvage Therapies After Anti‐BCMA CAR‐T Failure in Patients With Multiple Myeloma: A Meta‐Analysis of Response Rates. European Journal of Haematology, 116(5), 663-673. https://doi.org/10.1111/ejh.70123
Vancouver
Tomasik J, Shouval R, Gafter-Gvili A, Topiłko J, Bilicki D, Basak GW. Salvage Therapies After Anti‐BCMA CAR‐T Failure in Patients With Multiple Myeloma: A Meta‐Analysis of Response Rates. European Journal of Haematology. 2026;116(5):663-673. doi:10.1111/ejh.70123
BibTeX
@article{Tomasik2026,
author = {Tomasik, Jaromir and Shouval, Roni and Gafter-Gvili, Anat and Topiłko, Julia and Bilicki, Dominik and Basak, Grzegorz W},
title = {Salvage Therapies After Anti‐BCMA CAR‐T Failure in Patients With Multiple Myeloma: A Meta‐Analysis of Response Rates},
journal = {European Journal of Haematology},
year = {2026},
volume = {116},
number = {5},
pages = {663--673},
doi = {10.1111/ejh.70123}
}
EUVIMED